SPECIALTY QUANTITY LIMIT PROGRAM

SIGNIFOR LAR (pasireotide)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional guantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Signifor LAR 10 mg kit	1 kit per 28 days	Acromegaly: 40 mg once every 4 weeks (every 28 days)*
Signifor LAR 20 mg kit	1 kit per 28 days	20 mg every 4 weeks recommended as initial dose for
Signifor LAR 30 mg kit	1 kit per 28 days	moderately impaired hepatic function (maximum recommended dose 40 mg every 4 weeks)
Signifor LAR 40 mg kit	1 kit per 28 days	*May be increased to a maximum of 60 mg for patients
Signifor LAR 60 mg kit	1 kit per 28 days	who have not normalized growth hormone and/or age and sex adjusted insulin-like growth factor-1 levels after 3 months of treatment with Signifor LAR at 40 mg.
		Dose may be decreased, either temporarily or permanently, by 20 mg decrements for management of adverse reactions or over-response to treatment.
		Cushing's disease: 10 mg once every 4 weeks (every 28 days)*
		10 mg every 4 weeks recommended as initial dose for moderately impaired hepatic function (maximum recommended dose 20 mg every 4 weeks)
		*May be increased to a maximum of 40 mg for patients who have not normalized 24-hour urinary free cortisol (UFC) and who tolerate this dose after 4 months of treatment with Signifor LAR at 10 mg.
		Dose may be decreased, interrupted, or discontinued for management of adverse reactions or over-response to treatment.

Specialty Quantity Limit Signifor LAR P2018a.docx

© 2018 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.



III. REFERENCES

1. Signifor LAR [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; June 2018.

Specialty Quantity Limit Signifor LAR P2018a.docx

© 2018 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

